Discover Funding Opportunities

The PhRMA Foundation Predoctoral Fellowship in Drug Delivery provides support for promising students (U.S. and non-U.S. citizens) in advanced stages of training and thesis research in drug delivery research, including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, pharmaceutical biotechnology, or biomedical engineering. The fellowship provides $30,000 per year for up to 2 years (12, 18, or 24 months) to support doctoral candidates who have completed most of their pre-thesis requirements and are engaged in thesis research. Research areas could include formulation composition and drug delivery technologies, development of CMC processes for challenging chemical entities, and predictive approaches including modeling, simulation, and machine learning. Proposals must include a clearly defined therapeutic payload and target tissue, as well as rationale for dosing and pharmacokinetic/pharmacodynamic feasibility. This two-stage application process requires submission of a letter of intent followed by a full application for selected candidates.

The School of Pharmacy Prize for Excellence in Pharmaceutics is an academic award offered by University College Cork (UCC) in Ireland. This prize recognizes outstanding achievement in the field of Pharmaceutics and is awarded to the student with the best aggregated results in Pharmaceutics modules across the Bachelor of Pharmacy (BPharm) degree program. To be eligible, students must attain a pass in all qualifying modules (PF1012, PF2016, PF2017, PF3015, PF4015) with no compensation permitted. Examinations must be taken at the Summer Examination for the first time and at the first opportunity. Students who take exams at Supplemental Examination due to illness, injury, or other mitigating circumstances remain eligible. In the event of a tie, the prize amount is divided equally among qualifying students.

This is a 4-year PhD studentship in Organic Chemistry and Chemical Biology funded by AstraZeneca, based in the Department of Chemistry at the University of Cambridge and the AstraZeneca Discovery Centre. The project, jointly supervised by Prof David Spring (Cambridge) and Dr Nicholas Darton (AstraZeneca), focuses on "Improving the Stability of ADCs and their Formulations by Mitigating Degradation Pathways." The research involves Antibody-drug conjugates (ADCs), which have revolutionized targeted cancer therapy by delivering cytotoxic drugs to cancer cells with reduced systemic toxicity. However, their long-term stability is often compromised by aggregation and photooxidative degradation. The project will introduce both photostabilising and hydrophilic functionalities into ADCs, offering a novel route to enhance formulation stability and providing general insights for improving the stability of a wide range of ADCs. The work will involve both organic synthesis and chemical biology skills. Full funding is provided covering maintenance fees at £21,500 per annum and the University Composition Fee, with effect from 1 October 2026. The studentship is open to UK citizens or overseas students who meet UK residency requirements for home fees, or those able to augment funds to cover international student fees. Students will have access to extensive training opportunities, close supervision from primary and secondary PhD supervisors, and mentoring support.

This scholarship will fund a 3-year PhD candidature working in the Cancer, Ageing & Vaccine Laboratory (SHBS) at RMIT University. The project is a collaboration with chemists (SoS) to test gold compounds as anti-ovarian cancer therapeutics. The PhD candidate will contribute to determining the in vivo efficacy, pharmacokinetics, safety, off-target effects (peripheral and immunity) and biodistribution of lead gold-drug candidate(s) and pharmaceutical formulation development. As part of working towards a Phase I clinical trial, the gold-compounds will need to be tested for efficacy in ovarian cancer cell lines, organoids as well as immune cells from mice and humans. The lead drug candidates will be tested in a novel immunocompetent ovarian cancer animal model created by Professor Plebanski and Dr Andrew Stephens whereby fluorescent labelling of cancer cells allows for real-time study of cancer growth and treatment. Efficacy of the gold-compounds will be analysed by advanced live in-vivo imaging and immunohistochemistry.

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. This cooperative agreement supports organizations engaged in translational drug development research for Alzheimer's disease. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development of risk, diagnostic, prognostic, predictive, and prevention biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors for drug candidates developed in this program.

This project grant from the Swedish Research Council (Vetenskapsrådet) aims to provide researchers with freedom to formulate research ideas, methods, and implementation to solve a defined research task within a limited time. The grant focuses on building knowledge to reduce negative consequences on people's lives and health and on society as a result of viral diseases and pandemics, thereby preparing society for future pandemics. The funding encompasses research on knowledge gaps from a broad perspective including both basic virological research and fundamental viral disease mechanisms, as well as research on virus-caused pandemics and their effects on society and public health. This includes research on zoonoses, development of drugs, vaccines, diagnostics and treatment, how equitable and gender-equal health can be ensured during a pandemic, and appropriate organization, governance and coordination of important societal functions during a virus-caused pandemic. The grant supports research within one or more of five focus areas identified within the national research program on viruses and pandemics: (1) viruses, virus-caused disease states and fundamental disease mechanisms; (2) mechanisms for emergence and spread of zoonoses with pandemic potential and strategies for prevention and management of infection spread; (3) development of antiviral drugs, vaccines and diagnostics; (4) societal measures arising from pandemics and their effects on people's living conditions and health; (5) organization, governance and coordination of important societal functions during a pandemic (infrastructures).